ReviewCurrent opinion in allergy and clinical immunology2015
Effect of allergen-specific immunotherapy on CD4+ T cells.
Review in Current opinion in allergy and clinical immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 69 citations in OpenAlex.
- Cockroach immunotherapy modulates dominant T-cell responses independent of allergen extract content.The Journal of allergy and clinical immunology · 2025Trial
- CD8Nature communications · 2022Trial
- Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses.Allergy · 2022Trial
- Peanut oral immunotherapy differentially suppresses clonally distinct subsets of T helper cells.The Journal of clinical investigation · 2022Trial
- A phenotypically and functionally distinct human TScience translational medicine · 2017Trial
- Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies.The lancet. Gastroenterology & hepatology · 2017Trial
- The adeno associated viral vectored Dp12S vaccine effective alleviation of asthma symptoms in mice.NPJ vaccines · 2025Article
- Liver-targeted allergen immunotherapy rapidly and safely induces antigen-specific tolerance to treat allergic airway disease in mice.Science translational medicine · 2025Article
- T Cell Exhaustion in Allergic Diseases and Allergen Immunotherapy: A Novel Biomarker?Current allergy and asthma reports · 2025Review
- Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study.Nature communications · 2024Observational
- Mechanism differences in the start time of sublingual immunotherapy in a mouse allergic airway inflammation model.Scientific reports · 2024Article
- T-cell subset changes during the first year of pre-seasonal allergoid allergen-specific immunotherapy.Heliyon · 2023Article
- Erythema nodosum leprosum after allergen immunotherapy as initial presentation of lepromatous leprosy treated with novel multidrug regimen.JAAD case reports · 2023Article
- Redefining the human corneal immune compartment using dynamic intravital imaging.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Experimental observation of the effect of immunotherapy on CD4+ T cells and Th1/Th2 cytokines in mice with allergic rhinitis.Scientific reports · 2023Article
- Article
- AIT: New Avenues in Allergen Immunotherapy.Handbook of experimental pharmacology · 2022Article
- Th2A cells: The pathogenic players in allergic diseases.Frontiers in immunology · 2022Review
- Biomarkers of AIT: Models of prediction of efficacy.Allergologie select · 2022Review
- Roles of type 1 regulatory T (Tr1) cells in allergen-specific immunotherapy.Frontiers in allergy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThe aims of this review are to discuss the impact of chronic high-dose allergen exposure on allergen-specific CD4(+) T-cell subset during allergen-specific immunotherapy (AIT) and discuss recent advances supporting novel mechanisms for desensitization and tolerance induction during AIT. (Figure is included in full-text article.) RECENT
findingsNew technologies for direct molecular and cellular analysis have now provided an unprecedented opportunity to compare the functions and phenotypes of allergen-specific T cells at a single cell level, both in the context of disease and clinical intervention. Recent studies have demonstrated that AIT may restore tolerance by transiently inducing interleukin (IL)-10 producing T cells followed by selective deletion of allergen-specific TH2 cell subset. SUMMARY: With antigen-specific TH2 cells at the core of the allergic process in atopic individuals, the duration and dose of antigen exposure can be the driving force behind current AIT protocol. Mechanisms modulating allergen-specific CD4(+) T-cell responses may include autocrine IL-10 production to limit excessive TH2 cell effector responses, T-cell exhaustion, and preferential proallergic TH2 cell deletion allowing concurrent downregulating T-cell responses to emerge. Administration of AIT in the context of immune modulating strategies able to induce counter-regulatory immune response may lead to improved AIT with durable clinical benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.